半夏泻心汤治疗肠易激综合征疗效及安全性的Meta分析

Efficacy and Safety of Banxia Xiexin Decoction in the Treatment of Irritable Bowel Syndrome: A Meta-Analysis

目的分析半夏泻心汤治疗肠易激综合征的临床疗效及安全性。方法通过检索中国知网数据库(CNKI)、维普中文科技期刊数据库(VIP)、万方数据库及PubMed,Cochrane数据库的半夏泻心汤治疗肠易激综合征的临床随机对照试验,检索日期自建库至2018年9月1日,按Cochrane系统评价方法评价纳入研究的质量,采用RevMan5.3软件进行系统评价。结果共纳入12篇随机对照试验,涉及999例肠易激综合征患者。Meta分析结果显示,半夏泻心汤治疗肠易激综合征的总有效率、治愈率、复发率等均优于对照组[RR=0.22,95%CI(0.18,0.27),Z=9.05,P<0.01;RR=1.85,95%CI(1.45,2.37),Z=4.91,P<0.01;RR=0.23,95%CI(0.12,0.42),Z=4.67,P<0.01];在改变大便性状方面,两组比较差异无统计学意义[RR=-0.29,95%CI(-0.82,0.24),Z=1.08,P>0.05];只有1篇文献描述不良反应发生率。结论半夏泻心汤治疗肠易激综合征疗效显著,但在改变大便性状方面无差异。

Objective To analyze the clinical efficacy and safety of Banxia Xiexin Decoction in the treatment of irritable bowel syndrome(IBS).Methods Randomized controlled trials(RCTs)of Banxia Xiexin Decoction in the treatment of IBS were retrieved from CNKI,VIP,Wanfang data,PubMed and Cochrane databases from inception to September 1,2018.The quality of the study was evaluated according to Cochrane’s systematic evaluation method.RevMan5.3 software was used to systematically evaluate the included literature.Results Totally12 RCTs involving 999 patients with IBS were included.Meta-analysis showed that Banxia Xiexin Decoction was superior to the control group in the total effective rate[RR=0.22,95%CI(0.18,0.27),Z=9.05,P<0.01],cure rate[RR=1.85,95%CI(1.45,2.37),Z=4.91,P<0.01]and recurrence rate[RR=0.23,95%CI(0.12,0.42),Z=4.67,P<0.01]in the treatment of IBS.There was no significant difference in the change of stool characteristics between the two groups[RR=-0.29,95%CI(-0.82,0.24),Z=1.08,P>0.05].The incidence of adverse reactions was only described in 1 document.Conclusion Banxia Xiexin Decoction has obvious advantages in the treatment of IBS,but there is no difference in the change of stool characteristics.